Frontlight ResearchEarly access
Ovarian cancer trials in China
185 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking people68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 50
- Run by
- Peking University Third Hospital
See details and how to joinNCT07760012 - Phase 1/2Taking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - Phase 1/2Taking peoplePhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844 - No phaseTaking peopleStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery
- Where
- Huai'an
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Catherin Zhang
See details and how to joinNCT07860203 - Phase 1/2Taking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
- Age
- 18 years to 130 years
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - Phase 2Taking peopleNiraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 116
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06141265 - Phase 2Taking peopleRC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 54
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06420973 - Phase 2Not yet taking people in ChinaTrastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 53
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07843303 - Early phase 1Not yet taking people in ChinaNK521 in the Treatment of Advanced Solid Tumors
- Where
- Hefei
- Age
- 18 years to 65 years
- People
- 18
- Run by
- Base Therapeutics (Shanghai) Co., Ltd.
See details and how to joinNCT07657416 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 3Taking peopleA Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
- Where
- Beijing
- Age
- 18 years and over
- People
- 460
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07708753 - Phase 1/2Taking peopleA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
- Where
- Bengbu, Changsha
- Age
- 18 years and over
- People
- 60
- Run by
- Heronova Pharmaceuticals
See details and how to joinNCT06873555 - Phase 3Not yet taking people in ChinaPhase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
- Where
- Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luzhou, Nanchang, Nanjing, Nanning, Shanghai, Shaoguan, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xi’an, Xuzhou
- Age
- 18 years and over
- People
- 460
- Run by
- Hansoh BioMedical R&D Company
See details and how to joinNCT07821606 - Phase 3Taking peopleA Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
- Where
- Beijing, Taiyuan, Tangshan
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07822646 - Phase 1/2Taking peopleA Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 150
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06840002 - Phase 1Not yet taking people in ChinaSafety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 8
- Run by
- Yong He
See details and how to joinNCT07815951 - Phase 1Taking peopleA Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07676890 - Phase 1Taking peopleA Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07724106 - Phase 2Taking peopleA Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 171
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07714668 - Phase 2Not yet taking people in ChinaTR115 in ARID1A-Mutated Advanced Solid Tumors
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 50
- Run by
- Tarapeutics Science Inc.
See details and how to joinNCT07793318 - Phase 2Taking peopleRC48 in Combination With AK104 and Bevacizumab in OCCC
- Where
- Guanzhou
- Age
- 18 years to 75 years
- People
- 39
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06540729 - No phaseTaking peopleReal-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 1,920
- Run by
- Fudan University
See details and how to joinNCT07783022 - Phase 1Taking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - Phase 2Not yet taking people in ChinaTrastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 176
- Run by
- Sun Yat-sen University
See details and how to joinNCT07776171 - Phase 1Taking peopleA Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Where
- Beijing, Changsha, Guangzhou, Jinan, Jining, Shanghai, Shenyang, Shijiazhuang
- Age
- 18 years and over
- People
- 738 worldwide
- Run by
- NextCure, Inc.
See details and how to joinNCT06792552